Anglorand Securities Limited v Mudau & another

Mr Mudau (the plaintiff) claimed that in December 2001, he entered into an oral agreement with Anglorand Securities Ltd (the appellant) through its employee Rudolph Rashama, to purchase shares and invest R160,000. He deposited this amount into Anglorand's bank account on 4 December 2001. Mudau alleged that shares were never purchased, no investment booklet was provided, and his money was not refunded despite promises. Prior to this, Mudau had invested R300,000 with Cahn Shapiro Inc (through the same employee Rashama), which client base was acquired by Anglorand effective 1 March 2001 (but without assuming liabilities). Mudau's attorneys sent a letter of demand on 14 October 2002. On 24 October 2002, Anglorand's attorney responded denying any liability. Mudau issued summons on 16 August 2006, more than three years after the denial of liability. Anglorand pleaded prescription as a special plea. The High Court upheld Mudau's claim, rejecting the special plea.

• When did prescription commence to run in respect of the plaintiff's claim?
• Was the running of prescription interrupted by any acknowledgment of liability by the defendant?
• Whether the High Court misdirected itself in determining the special plea of prescription as a preliminary issue?

The appeal was allowed with costs. The order of the High Court was set aside and replaced with: 'The second defendant's special plea of prescription is upheld and the plaintiff's claim is dismissed with costs.'

1. Prescription commences to run as soon as a debt is due, which occurs when the creditor has a complete cause of action - meaning all facts necessary to enforce the claim exist and the creditor knows or should reasonably know of the debtor's identity and the facts giving rise to the debt (applying section 12(1) of the Prescription Act 68 of 1969). 2. A debt becomes due when it is immediately claimable by the creditor and immediately payable by the debtor, which occurs when the debtor expressly denies liability. 3. For interruption of prescription under section 14(1), there must be an express or tacit acknowledgment of liability by the debtor. This requires acknowledgment that the debt exists and that the debtor is liable at the time the statement is made. The acknowledgment must cover every element of the debt and exclude any defense as to its existence. 4. A letter from a third party (even a related company) does not constitute an acknowledgment of liability by the defendant. 5. The creditor bears the onus of proving that prescription was interrupted.

The Court noted that Hetisani J in the High Court described Anglorand's prescription defense as 'efforts to escape liability, by mere tactics based on legal technicalities.' Ponnan JA did not expressly criticize this characterization but implicitly rejected it by upholding the prescription defense. The judgment also touched on the distinction between separate corporate entities (Cahn Shapiro Inc and Anglorand Securities Ltd), noting that when only a client base is purchased without assuming liabilities, the acquiring company is not liable for claims relating to transactions before the acquisition date. While this was relevant to understanding the facts, it was not strictly necessary for the decision on prescription. The Court also observed that the High Court judge misconstrued the evidence of Ms Taljaard, who testified that Anglorand never told Mudau it would pay and consistently denied liability, contrary to the judge's finding that Mudau was told his claim had been lodged with Loss Adjustors.

This case provides important guidance on the application of the Prescription Act 68 of 1969 in South African law. It clarifies when prescription commences to run (when the debtor disputes liability and the creditor has knowledge of this), and what constitutes an acknowledgment of liability sufficient to interrupt prescription under section 14(1). The case emphasizes that an acknowledgment must cover every element of the debt and exclude any defense as to its existence. It also distinguishes between different corporate entities and confirms that liabilities are not automatically transferred when a client base is acquired. The judgment reinforces that prescription is a matter of fact, not law, and that the creditor bears the onus of proving interruption of prescription.